Insulin therapy is the only option for type 1 diabetes (T1D) patients. Yet, this therapy is suboptimal. Central problem remains to achieve a proper glycemic control without the risk of life- threatening hypoglycemia and ketoacidosis. Diatheris is a spinoff from University of Geneva with the goal of developing a new therapeutic solution to overcome these limitations and improve T1D management. Diatheriss lead program consists in developing a proprietary game-changing approach based on a small protein called S100A9. S100A9 treatment is exploiting an insulin-independent pathway, which has shown remarkable results in combination with low-dose insulin, to improve glycemic control (normalizing glycemia) without the risk of hypoglycemia and ketoacidosis.
Location: Switzerland, Geneva
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | Venture Ki... | venturekic... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 17.11.2023 | InnoBooster accelerates four Life sciences solutions | Founded by Giorgio Ramadori, as a spin-off of the University of Geneva, DIATHERIS aspires to impro... | startuptic... |
| 23.08.2023 | CHF 40,000 for adjunct treatment to insulin therapy, CAR-T c... | DIATHERIS: Adjunct treatment to insulin therapy Type 1 diabetes (T1D) patients face significant cha... | venturekic... |
| 27.06.2023 | Biosimo wins the >>Venture>> grand prize | The concluded edition of >>venture>>, Switzerland’s leading startup competition, recei... | startuptic... |
| 22.05.2023 | Top 18 startups in the >>venture>> competition p... | The latest edition of >>venture>>, one of the most long-standing Swiss startup competi... | startuptic... |
| 09.05.2023 | Startups developing meat analogs, the next-gen search engine... | Advection Engineering: Marbling meat analogs The demand for reduced meat consumption has led food c... | venturekic... |